In this study, we investigated the effect of the dipeptidyl peptidase-4 (DPP-4) inhibitor anagliptin on NASH and HCC development in MC4R-KO mice. The gene discussed is DPP4; the disease is metabolic dysfunction-associated steatohepatitis.